Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27636329 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL31421622 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL28370477 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL11392390 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL8999815 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL12254212 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL665388 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL1986603 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL8999836 | 1.00 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL1759484 | 0.98 | CYP1A2 (0.56) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | claimed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | claimed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| CN-102459416-B | Process for production of polyhydroxyimide | NISSAN CHEMICAL IND LTD | 2014-06-18 | — | — | CN | claimed |
| EP-4074807-B1 | COMPOSITIONS COMPRISING A FLUOROOLEFIN | CHEMOURS CO FC LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-114829539-B | Photochromic curable composition and photochromic optical article | 株式会社德山 | 2024-09-06 | — | — | CN | disclosed |
| EP-3543310-B2 | COMPOSITIONS COMPRISING HFC-1234YF AND HFC-32 | CHEMOURS CO FC LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3543310-B2 | COMPOSITIONS COMPRISING HFC-1234YF AND HFC-32 | CHEMOURS CO FC LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3299435-B1 | METHOD OF PREPARING A COMPOSITION COMPRISING HFC-1234YF | CHEMOURS CO FC LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20020013479-A1 | Process and catalyst for the production of gamma-butyrolactones | HALDOR TOPSOE A/S (DK) | 2002-01-31 | — | — | US | disclosed |
| CN-1330070-A | Perfume parent | GIVAUDAN SA (CH) | 2002-01-09 | — | — | CN | disclosed |
| EP-1167361-A2 | Process and catalyst for the production of y-butyrolactones | Haldor Topsoe A/S (DK) | 2002-01-02 | — | — | EP | disclosed |
| EP-1167362-A1 | Fragance precursors | Givaudan SA (CH) | 2002-01-02 | — | — | EP | disclosed |
| CN-1329000-A | Method for producing gamma-butyrolatone and catalyst | HALDOR TOPSOE AS (DK) | 2002-01-02 | — | — | CN | disclosed |
| US-4285868-A | LACTONIZATION | MOBIL OIL CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| US-4175089-A | Preparation of gamma-butyrolactones | MOBIL OIL CORPORATION (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013479-A1 | Process and catalyst for the production of gamma-butyrolactones | OGDH, HSD17B12, SCO2 | CYP1A2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.